Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) transplantation is a promising antifibrotic strategy but facing clinical controversies.Inspired by advances in nanomedicine, we aimed to bypass these clinical barriers of MSCs by identifying the key antifibrotic molecule of MSCs and developing a specific liver-targeting nanocarrier.Methods: Cytokines secreted by MSCs were examined with serum stimulation of cirrhotic patients.Immunohistochemistry, microarray, immunoblotting, and quantitative real-time PCR (qRT-PCR) were applied to identify the critical antifibrotic cytokine and to discover its role in modulating antifibrotic effects.Biomineralization method was used to prepare calcium phosphate nanoparticles (NPs).The targeting and therapeutic efficiency of NPs were evaluated by in vivo imaging and biochemical studies on fibrotic mice induced by CCl4.Results: The stimulated MSCs exhibited high-level expression of Tumor necrosis factor (TNF)-stimulated gene 6 (TSG-6).On animal study, exogenous administration of TSG-6 alone can ameliorate liver fibrosis while TSG-6 knocked MSCs (Lv-TSG-6 MSCs) lost antifibrotic effects.Further studies verified the importance of TSG-6 and identified its antifibrotic mechanism by modulating M2 macrophages and increasing matrix metalloproteinase 12 (MMP12) expression.Additionally, we found a feedback loop between TSG-6, MMP12 and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), which may improve our understanding of the aggravating process of cirrhosis and antifibrotic mechanisms of TSG-6 and MSCs.Based on these findings, we developed calcium phosphate nanoparticles (CaP@BSA NPs) by biomineralization method using bovine serum albumin (BSA) as the biotemplate.Imaging tracking and drug loading studies showed specific liver targeting and high TSG-6 loading efficacy of as-prepared CaP@BSA NPs.In vivo therapeutic study further demonstrated the improved therapeutic effects of TSG-6 loaded CaP@BSA.Conclusions: TSG-6 was a major antifibrotic cytokine of MSCs, TSG-6 loaded CaP@BSA NPs showed specific liver accumulation and improved therapeutic effects, which indicated translational potentials of CaP@BSA as a promising drug carrier for the liver disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naghavi, M., Abajobir, A. A., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abera, S. F., Aboyans, V., Adetokunboh, O., Afshin, A., Agrawal, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32152-9 · Cited by 4,821
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898 · cited 1×
“By reviewing prior works, TSG-6 aroused our interest because TSG-6 showed strong immunomodulatory effects and tissue-protective properties in many disease models [31-37].”
BackgroundMesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445 · cited 1×
“Therefore, by identifying specific antifibrotic molecules and directly using these effectors instead [16], we could avoid cell transplantation and bypass above barriers of MSCs.”
BackgroundKharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 1×
“Several clinical trials have shown MSCs contribution to liver regeneration and function restoration [4-10].”
BackgroundZhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 1×
“Several clinical trials have shown MSCs contribution to liver regeneration and function restoration [4-10].”
BackgroundSuk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303 · cited 1×
“Several clinical trials have shown MSCs contribution to liver regeneration and function restoration [4-10].”
Background
Cited by
Fu, L., Wan, Y., Qi, C., He, J., Li, C., Yang, C., Xu, H., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202006892 · Cited by 820
Self-citationMacrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Fu, L.-H., Hu, Y.-R., Qi, C., He, T., Jiang, S., Jiang, C., He, J., Qu, J., Lin, J., & Huang, P. (2019) · ACS Nano · doi:10.1021/acsnano.9b05836 · Cited by 437
Self-citationTian, S., Zhou, X., Zhang, M., Cui, L., Li, B., Liu, Y., Su, R., Sun, K., Hu, Y., Yang, F., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03010-y · Cited by 144
Self-citationLiver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
Metadata
- Authors
- Wang, M., Zhang, M., Fu, L., Lin, J., Zhou, X., Zhou, P., Huang, P., Hu, H., & Han, Y.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 1
- Pages
- 36-49
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2982585013
- Cited by
- 81
- References
- 6
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.